How Advocates, Clinicians, and Researchers Can Collaborate on Sickle Cell Disease
Published: 10 Apr 2026
Sickle cell disease affects approximately 8 million people globally and more than 100,000 people in the United States. It is one of the most common genetic disorders in the world — and one of the most underfunded.
Despite decades of research, people living with sickle cell disease continue to face fragmented care, significant pain burden, and a healthcare system that often fails to understand or prioritize their needs. The racial and geographic disparities in sickle cell care are well-documented and deeply unjust.
Progress requires collaboration. Not the aspirational kind — the structured, accountable, cross-sector kind that produces real outcomes for real patients.
This guide is a practical resource for patient advocates, clinicians, and researchers who want to build partnerships in the sickle cell disease space that actually work.
Why the Sickle Cell Community Needs Structured Collaboration Now
The last decade has seen meaningful advances in sickle cell disease research and treatment. Gene therapy approaches, new disease-modifying therapies, and a growing evidence base for hydroxyurea use have created new possibilities for patients.
But translating research into equitable patient access requires more than scientific breakthroughs. It requires:
- Patient advocacy organizations that can connect patients to new treatments and trials
- Clinicians who have the information and resources to educate patients and families
- Researchers who have access to patient populations and community input on trial design
- Industry partners willing to invest in a disease that has historically been neglected
- Community trust built over years of consistent, culturally competent engagement
None of these can be created or sustained in isolation.
The Current State of Sickle Cell Disease Collaboration
The sickle cell community has a history of advocacy-driven progress. The Sickle Cell Disease Association of America, the Sickle Cell Warriors, and dozens of regional and community-based organizations have built real community trust and pushed for research investment, policy change, and patient education.
What has been historically missing is the infrastructure to connect these community assets with the clinical and research ecosystem in a structured, scalable way.
Clinical researchers often don’t know which advocacy organizations to approach or they’ve been engaging the same organizations for an extended period of time in the same way, missing out on opportunities to expand their impact. Advocacy organizations often don’t know which research teams are working on questions their communities care about. Biotech companies looking to develop or commercialize sickle cell therapies struggle to identify community partners they can trust or wide adoption of their therapies.
The result is missed opportunities where goodwill and expertise exist but coordination is missing.
This is the problem Elevate Impact was built to solve — starting with the sickle cell community.
The Three Partnership Types That Matter Most in Sickle Cell Disease
1. Clinical and Community Partnerships
These partnerships connect clinical teams — hematologists, nurse practitioners, care coordinators — with patient advocacy organizations and community health workers.
The goal is coordinated care: ensuring that patients living with sickle cell disease have access to the most current treatment options, that they are not lost to follow-up during disease flares, and that clinical teams have the community context to provide culturally competent care.
Effective clinical-community partnerships in the sickle cell space typically involve shared patient education resources, regular communication between clinical and community teams, and joint protocols for managing transitions in care.
2. Research and Advocacy Partnerships
These partnerships connect academic and clinical researchers with patient advocacy organizations to improve the relevance, reach, and equity of sickle cell research.
They include community-based participatory research, patient advisory roles in clinical trial design, and community engagement efforts to increase clinical trial enrollment among underrepresented populations.
Research teams that partner authentically with advocacy organizations consistently report faster recruitment, lower attrition, and better community trust — all of which improve the quality of research.
3. Industry and Advocacy Partnerships
These partnerships connect biotech and pharmaceutical companies developing sickle cell therapies with the advocacy organizations that have the trust of the patient community.
As noted above, these relationships are becoming more important as patient engagement becomes a formal expectation in drug development. Advocacy organizations that can demonstrate organizational capacity, documented community trust, and clear partnership frameworks are best positioned to attract and sustain these relationships.
What Good Collaboration Looks Like in the Sickle Cell Community
The best sickle cell partnerships share a few characteristics.
They start from community need, not organizational interest
The most credible and durable partnerships in the sickle cell space are those that were designed around a question the community itself identified — not around what was convenient for a research team or a company’s development timeline.
They involve patients and families as partners, not subjects
Patient-centered research and engagement means involving people with sickle cell disease in the design, implementation, and communication of partnership activities — not just as recruitment targets or testimonial sources.
They invest in cultural competency
Sickle cell disease disproportionately affects Black Americans, and the history of medical mistrust in this community is real and warranted. Organizations that engage without acknowledging or addressing this history do not build lasting partnerships.
They measure and share outcomes
Community partnerships that demonstrate impact attract more investment. Clinical partnerships that document outcomes build the evidence base for continued collaboration. Research partnerships that share findings with the community they studied build trust for future work.
Building a Sickle Cell Partnership: A Starting Point
Whether you’re coming from the advocacy side, the clinical side, or the research side, the first steps are similar.
Define what you’re trying to accomplish
A vague desire to “work together” is not a partnership. What specific outcome are you trying to achieve for patients? Be as concrete as possible.
Identify who else needs to be involved
Who has the expertise, the community trust, or the resources you don’t have? Make a list before you start making calls.
Do your homework
Before approaching any organization, understand their work, their community, their capacity, and their history. Cold outreach that demonstrates you’ve paid attention is significantly more effective than generic partnership asks.
Start small
A joint educational event, a shared webinar, a co-authored resource — these are low-stakes ways to test a partnership before committing to a larger engagement.
Build in accountability from the start
What will each party contribute? What are the timelines? How will you measure success? Document this before the work begins.
How Elevate Impact Is Supporting Sickle Cell Collaboration
Elevate Impact chose to begin with the sickle cell community for specific reasons.
It is one of the most underfunded rare disease areas. It disproportionately affects Black Americans, making it a clear health equity priority. And the advocacy ecosystem, while strong in many ways, lacks the structured partnership infrastructure needed to maximize its impact.
Our platform brings together patient advocacy leaders, clinicians, researchers, and industry partners in a shared digital ecosystem — with the tools to facilitate the specific kinds of partnerships described in this guide.
Our monthly roundtables and webinars are focused on the collaboration and partnership questions that matter most to the sickle cell community.
Our toolkit provides frameworks for partnership governance, impact measurement, and equity accountability. And our community is growing — bringing together people who are serious about doing this work well.
If you’re working in the sickle cell space and want to build better partnerships, we’d love to have you as part of the Elevate Impact community.
Frequently Asked Questions
Major national organizations include the Sickle Cell Disease Association of America (SCDAA), the American Society of Hematology, and the Sickle Cell Warriors. There are also dozens of regional and community-based organizations across the country, particularly in areas with large populations affected by the disease.
Start by learning about the advocacy organizations active in your region or patient population. Attend community events. Offer clinical expertise in support of their education programs. Ask how your expertise can serve their community — not what they can do to support your work. Relationships built on genuine contribution to community need are the most durable.
Community-based participatory research approaches, community advisory boards, and structured advocacy partnerships are the most effective strategies for improving enrollment in sickle cell clinical trials. Addressing historical mistrust, providing transparent information about trial risks and benefits, and ensuring that the community has meaningful input on research design are essential components.
Biotech and pharmaceutical companies can provide financial support, technical expertise, and access to clinical resources. In exchange, advocacy organizations provide community trust, patient insight, and recruitment support. The most effective industry-advocacy partnerships are those where both parties invest in the relationship before making specific asks.
Elevate Impact’s platform, toolkit, and community are specifically designed for the rare disease space, with sickle cell disease as our primary starting focus. We facilitate partnerships between patient advocates, clinicians, researchers, and industry partners through structured frameworks, shared community infrastructure, and regular collaborative programming.
Yes. Our platform is accessible globally, and our GSC data shows interest from researchers and advocates in countries including Nigeria, India, and Ethiopia — all regions significantly affected by sickle cell disease. We welcome international collaborators.
The sickle cell community has everything it needs to accelerate progress — community trust, scientific momentum, and increasing industry investment. What has been missing is the infrastructure to connect these assets in a structured, equitable, and measurable way.
That’s what we’re building at Elevate Impact.
The partnerships that will make the most difference for people living with sickle cell disease are the ones that are designed with the community, that measure what they accomplish, and that invest in the long-term relationship rather than the short-term transaction.
If you’re ready to build those partnerships, we’re ready to help.
